July 25, 2011
Inostics GmbH has successfully passed the external proficiency test for KRAS more >>
Individualized Diagnostics
Inostics has the goal to improve cancer drug development and standard patient management by offering state of the art molecular diagnostic tools for the non-invasive detection and monitoring of tumors in blood samples.
The core competency of Inostics is centered around the detection of genetic changes, such as somatic mutations, in a patients’ blood or tissue.
Sensitive Mutation Detection
BEAMing Technology for the detection of mutations in Plasma/Serum and Tissue. more >>
Mutation Discovery
Exon Sequencing for discovery and detection of mutations from tumor tissue. more >>
Companion Diagnostics Development
Design, implementation and qualification of new companion diagnostics. more >>